Compare PDS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | GERN |
|---|---|---|
| Founded | 1951 | 1990 |
| Country | Canada | United States |
| Employees | N/A | 229 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.1M | 1.1B |
| IPO Year | 1998 | N/A |
| Metric | PDS | GERN |
|---|---|---|
| Price | $96.30 | $1.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $114.50 | $2.17 |
| AVG Volume (30 Days) | 126.3K | ★ 17.5M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.09 | $26.91 |
| Revenue Next Year | $2.10 | $43.75 |
| P/E Ratio | $884.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.20 | $1.04 |
| 52 Week High | $97.13 | $2.01 |
| Indicator | PDS | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 72.77 | 47.03 |
| Support Level | $54.77 | $1.23 |
| Resistance Level | N/A | $1.68 |
| Average True Range (ATR) | 2.91 | 0.11 |
| MACD | 0.25 | -0.01 |
| Stochastic Oscillator | 92.55 | 41.43 |
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.